McKesson (NYSE:MCK) Lifted to Sell at ValuEngine
McKesson (NYSE:MCK) was upgraded by investment analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Thursday, ValuEngine reports.
MCK has been the topic of a number of other reports. Credit Suisse Group began coverage on McKesson in a report on Monday, July 22nd. They set a “neutral” rating and a $143.00 target price on the stock. TheStreet raised McKesson from a “c” rating to a “b” rating in a report on Wednesday, July 31st. Wolfe Research lowered McKesson from an “outperform” rating to a “peer perform” rating in a report on Monday, August 5th. Bank of America set a $160.00 target price on McKesson and gave the stock a “buy” rating in a report on Wednesday, July 31st. Finally, JPMorgan Chase & Co. began coverage on McKesson in a report on Monday, July 22nd. They set an “overweight” rating and a $164.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $148.70.
Shares of NYSE:MCK traded up $1.27 during trading on Thursday, hitting $147.76. 1,846,163 shares of the company were exchanged, compared to its average volume of 1,498,682. The stock has a market cap of $27.65 billion, a price-to-earnings ratio of 10.89, a P/E/G ratio of 1.48 and a beta of 1.13. McKesson has a fifty-two week low of $106.11 and a fifty-two week high of $150.20. The firm has a fifty day moving average price of $142.04 and a two-hundred day moving average price of $129.09. The company has a current ratio of 1.01, a quick ratio of 0.58 and a debt-to-equity ratio of 1.14.
In other news, CEO Brian Scott Tyler sold 1,488 shares of the company’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $125.49, for a total transaction of $186,729.12. Following the completion of the sale, the chief executive officer now directly owns 12,192 shares in the company, valued at approximately $1,529,974.08. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director M Christine Jacobs sold 1,296 shares of the company’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $146.65, for a total value of $190,058.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 4,704 shares of company stock worth $625,131. Insiders own 0.88% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. Cerebellum GP LLC bought a new stake in shares of McKesson during the 1st quarter valued at $318,000. Commonwealth Equity Services LLC lifted its position in shares of McKesson by 1.0% during the 2nd quarter. Commonwealth Equity Services LLC now owns 46,991 shares of the company’s stock worth $6,315,000 after buying an additional 472 shares during the last quarter. Busey Wealth Management lifted its position in shares of McKesson by 7.1% during the 2nd quarter. Busey Wealth Management now owns 26,511 shares of the company’s stock worth $3,562,000 after buying an additional 1,768 shares during the last quarter. World Asset Management Inc lifted its position in shares of McKesson by 27.0% during the 1st quarter. World Asset Management Inc now owns 17,543 shares of the company’s stock worth $2,054,000 after buying an additional 3,734 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its position in shares of McKesson by 10.3% during the 2nd quarter. Quadrant Capital Group LLC now owns 2,498 shares of the company’s stock worth $328,000 after buying an additional 233 shares during the last quarter. Hedge funds and other institutional investors own 89.65% of the company’s stock.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Featured Story: Death Cross
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.